SIGNET THERAPEUTICS
Signet Therapeutics is a biopharmaceutical startup focusing on developing innovative targeted cancer drugs using novel disease models.
SIGNET THERAPEUTICS
Industry:
Biotechnology Life Science
Founded:
2020-01-01
Address:
Newton, Massachusetts, United States
Country:
United States
Status:
Active
Total Funding:
20 M USD
Similar Organizations
Acthera Therapeutics
Acthera Therapeutics is developing an innovative nanotechnology-based platform for the controlled and targeted drug delivery
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Rectify Pharmaceuticals
Rectify Pharmaceuticals is a biotechnology company developing Positive Functional Modulators (PFMs), disease-modifying therapeutics.
Renovacor
Renovacor is a biopharmaceutical company that focuses on developing transformative gene therapy‑based treatments for cardiovascular disease.
Simcha Therapeutics
Simcha Therapeutics is a biopharmaceutical company developing engineered cytokine immunotherapy for cancer.
Voyager Therapeutics
Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
Current Employees Featured
Founder
Investors List
Tiantu Capital
Tiantu Capital investment in Seed Round - Signet Therapeutics
Sky9 Capital
Sky9 Capital investment in Seed Round - Signet Therapeutics
Blue Ocean Capital
Blue Ocean Capital investment in Seed Round - Signet Therapeutics
Yael Capital Management Limited
Yael Capital Management Limited investment in Seed Round - Signet Therapeutics
5Y Capital
5Y Capital investment in Seed Round - Signet Therapeutics
Tiantu Capital
Tiantu Capital investment in Seed Round - Signet Therapeutics
Sky9 Capital
Sky9 Capital investment in Seed Round - Signet Therapeutics
More informations about "Signet Therapeutics"
Signet Therapeutics - Crunchbase Company Profile
Signet Therapeutics is a biopharmaceutical startup focusing on developing innovative targeted cancer drugs using novel disease models.See details»
Signet Therapeutics - Crunchbase Company Profile
Signet Therapeutics is a cutting-edge firm that conducts research and development on cancer-targeted drugs.See details»
Signet Therapeutics Inc. - LinkedIn
Signet Therapeutics is a clinical-stage biotech company pioneering the development of first-in-class targeted cancer therapies using organoids and AI. Our lead program, SIGX1094, has entered Phase ...See details»
Signet Therapeutics 2025 Company Profile: Valuation, …
Information on valuation, funding, cap tables, investors, and executives for Signet Therapeutics. Use the PitchBook Platform to explore the full profile.See details»
Signet Therapeutics - Org Chart, Teams, Culture & Jobs | The Org
View Signet Therapeutics' up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
Signet Therapeutics - VentureRadar
"Signet Therapeutics is developing targeted small molecule cancer drugs using novel disease models. By strategically collaborating with AI drug R&D company XtalPi, Signet aims to …See details»
Signet Therapeutics Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Signet Therapeutics of Shenzhen, Guangdong. Get the latest business insights from Dun & Bradstreet.See details»
Signet Therapeutics and Jennio Biotech Join Forces to Advance …
Sep 12, 2024 Signet Therapeutics, a pioneering biopharmaceutical company in China specializing in cancer targeted therapies based on organoid disease models and artificial …See details»
World’s First Potential Target Therapy for Diffuse Gastric Cancer ...
Feb 20, 2025 BOSTON & SHENZHEN, China-- (BUSINESS WIRE)--Signet Therapeutics, a clinical-stage biotech company leveraging organoid- and AI-driven cancer drug discovery, …See details»
Signet Therapeutics – Startups.Bio
Oct 30, 2021 Founded in 2020, Signet Therapeutics is developing targeted small molecule cancer drugs using novel disease models. Dr. Haisheng Zhang, CEO of Signet Therapeutics, and his core team members originate from Dana-Farber …See details»
Signet Therapeutics | VentureRadar
Signet Therapeutics is developing targeted small molecule cancer drugs using novel disease models. By strategically collaborating with AI drug R&D company XtalPi, Signet aims to …See details»
Signet Therapeutics Announces IND Approval by the FDA for …
BOSTON, July 02, 2024--Signet Therapeutics, a biotech company using organoid disease models and AI to advance targeted cancer therapy, today announced that the FDA has granted its IND …See details»
Signet Therapeutics - Funding, Financials, Valuation & Investors
Signet Therapeutics is a cutting-edge firm that conducts research and development on cancer-targeted drugs.See details»
Signet Therapeutics gets a $10M top-up for next-gen cancer bets
Oct 29, 2021 Little U.S.-China startup Signet Therapeutics has bagged a second seed round worth around $10 million as plots a path to the clinic.See details»
Signet Therapeutics - Funding, Financials, Valuation & Investors
Signet Therapeutics is a biopharmaceutical startup focusing on developing innovative targeted cancer drugs using novel disease models.See details»
FDA Approves Signet Therapeutics' IND Application for sigx1094 …
Jul 5, 2024 Signet Therapeutics, a biotechnology company specializing in targeted cancer therapy, has received FDA approval for its Investigational New Drug (IND) application for …See details»
World’s First Drug Candidate developed by Organoid and AI …
NEW YORK-- (BUSINESS WIRE)-- Signet Therapeutics (“Signet”), a clinical-stage biotech company leveraging organoids and AI to develop first-in-class cancer therapies, today …See details»
Stomach Cancer (Signet Therapeutics) - Drug Targets, Indications ...
Stomach Cancer (Signet Therapeutics): a FAK inhibitors Drug, Initially developed by Signet Therapeutics, Inc., Now, its global highest R&D status is Preclinical, Mechanism: FAK …See details»
Scientists discover how to reactivate cancer’s molecular “kill switch ...
Mar 13, 2025 Discovery could open door to game-changing RNA-based multi-cancer therapeutics (Farmington, Conn. – March 13, 2025) – Alternative RNA splicing is like a movie …See details»
Signet Therapeutics | VentureRadar
Signet Therapeutics is developing targeted small molecule cancer drugs using novel disease models. By strategically collaborating with AI drug R&D company XtalPi, Signet aims to …See details»